Table 5 Summary of efficacy outcomes in... | American Society of Hematology

Table 5

Summary of efficacy outcomes in patients treated with lenalidomide monotherapy

Median values, mo	Overall, N = 222	CR + PR, n = 58	CR + PR + MR, n = 98
Progression-free survival	4.9*	14.5	10.4
Time to progression	5.2†	14.5	10.4
Overall survival	23.2‡	33.9	28.0

Median values, mo	Overall, N = 222	CR + PR, n = 58	CR + PR + MR, n = 98
Progression-free survival	4.9*	14.5	10.4
Time to progression	5.2†	14.5	10.4
Overall survival	23.2‡	33.9	28.0

CR indicates complete response; MR, minimal response; and PR, partial response.

Patients who had disease progression or died: 73%.

Patients who had disease progression: 69%.

Patients who died: 60%.